Hi Shelly You seem pretty close to the money from what I can ascertain. I understand Shaw Stockbrockers are undertaking an indepth research report on SLT. I've also heard they are nibbling away at the stock since the roadshow, so I take it their report is going to be positive.
With the Hep E deal in the bag it appears they are finalising arrangements for a Hep A deal and negotiations regarding the big one - Hep C - are being carried out concurrently with players in the US seeking exclusive distribution rights as they would with something as big as Hep C. Let's wait for the Shaw research report to hit the table but I reckon there'll be a slow steady increase in support in the lead up to the report because we all know the walls talk. Somebody earlier called $1.80. That's probably conservative, but I wouldn't have a clue so do your own research.
Cheers The Cloud
SLT Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
